Satellos Bioscience 2026 shareholder voting results

Satellos Bioscience Inc. reported the results of its annual shareholder meeting held virtually on June 17, 2026.

Rhea-AI Filing Summary

Satellos Bioscience Inc. reported the results of its annual shareholder meeting held virtually on June 17, 2026. Shareholders elected all nominated directors, with support levels generally very high.

Turnout was solid, with approximately 55.33% of issued and outstanding shares represented in person or by proxy. Most directors received about 99% of votes cast in favour. Stephanie Brown received 92.22% support, and Iris Loew-Friedrich received 83.76% support, while all other nominees were supported by at least 99.69% of votes cast.

Key Figures

Meeting turnout: 55.33% of shares Votes for Franklin M. Berger: 9,478,576 votes (99.99% for) Votes for Stephanie Brown: 8,741,404 votes (92.22% for) +2 more

5 metrics

Meeting turnout 55.33% of shares Issued and outstanding shares represented at June 17, 2026 meeting

Votes for Franklin M. Berger 9,478,576 votes (99.99% for) Director election at June 17, 2026 meeting

Votes for Stephanie Brown 8,741,404 votes (92.22% for) Director election at June 17, 2026 meeting

Votes for Iris Loew-Friedrich 7,939,800 votes (83.76% for) Director election at June 17, 2026 meeting

Votes for Mark Nawacki 9,477,041 votes (99.98% for) Director election at June 17, 2026 meeting

Key Terms

Report of Voting Results, National Instrument 51-102, management information circular, foreign private issuer

4 terms

Report of Voting Results regulatory

"Exhibit 99.1 Report of Voting Results Satellos Bioscience Inc."

National Instrument 51-102 regulatory

"In accordance with Section 11.3 of National Instrument 51-102, the following briefly describes"

National Instrument 51-102 is a Canadian securities rule that requires public companies to regularly publish clear, standardized information about their finances and significant developments, such as quarterly and annual reports, management discussion and analysis, and notices of material changes. For investors it acts like a rule forcing businesses to keep their financial “windows” clear and up to date, making it easier to compare companies, spot risks, and make informed decisions.

management information circular regulatory

"Full details of the matters are set out in the Company’s management information circular dated May 14, 2026"

A management information circular is a document sent to shareholders ahead of a company meeting that explains who is asking for votes, what decisions will be made, and why management recommends a particular outcome. Like an instruction booklet and argument sheet combined, it lays out details such as board nominees, executive pay, major transactions and any conflicts, helping investors decide how to vote and judge whether leadership choices could affect the company’s future value.

foreign private issuer regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Satellos Bioscience (MSLE) announce in its June 2026 Form 6-K?

Satellos Bioscience reported voting results from its June 17, 2026 annual shareholder meeting. Shareholders elected all nominated directors, with turnout of about 55.33% of issued and outstanding shares, and most directors receiving over 99% support on votes cast.

How many Satellos Bioscience (MSLE) shares were represented at the 2026 shareholder meeting?

Approximately 55.33% of Satellos Bioscience’s issued and outstanding shares were represented at the June 17, 2026 annual meeting. This figure includes shares present in person and by proxy, indicating a majority of the company’s equity participated in approving the board slate.

Which Satellos Bioscience (MSLE) directors received the highest support in 2026 voting?

Franklin M. Berger received 9,478,576 votes for, equal to 99.99% support, one of the highest levels among nominees. Several others, including Frank Gleeson, Selwyn Ho, Geoff Mackay, Adam Mostafa, and Mark Nawacki, each received at least 99.69% of votes in favour.

Which Satellos Bioscience (MSLE) directors had comparatively lower support in the 2026 vote?

Stephanie Brown and Iris Loew-Friedrich received relatively lower, though still strong, support. Stephanie Brown earned 8,741,404 votes for, or 92.22%, while Iris Loew-Friedrich received 7,939,800 votes for, or 83.76%, with the remainder voted against their election to the board.

When was Satellos Bioscience’s 2026 annual shareholder meeting held and how was it conducted?

Satellos Bioscience’s 2026 annual shareholder meeting was held virtually on June 17, 2026. Shareholders participated remotely, and voting outcomes were later summarized in a Report of Voting Results filed as an exhibit to a Form 6-K, in accordance with National Instrument 51-102.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 05:00 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

(Commission File No. 001-43107)

SATELLOS BIOSCIENCE INC.

(Translation of registrant’s name into English)

15 Allstate Parkway, Suite 600

Markham, Ontario, Canada, L3R 5B4

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☐               Form 40-F ☒

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

Exhibit	Description
99.1	Report of Voting Results

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Satellos Bioscience Inc.
	By:	/s/ Elizabeth Williams, CPA, CA
	Name:	Elizabeth Williams, CPA, CA
	Title:	Chief Financial Officer

Date: June 17, 2026

Exhibit 99.1

Report of Voting Results

Satellos Bioscience Inc.

In accordance with Section 11.3 of National Instrument 51-102, the following briefly describes the matters voted upon and the outcome of the votes at the annual meeting of shareholders of Satellos Bioscience Inc. (the “Company”) held virtually on June 17, 2026 (the “Meeting”). Full details of the matters are set out in the Company’s management information circular dated May 14, 2026, which is available on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov).

1. By resolution passed by way of ballot, each of the nominees for election as directors was elected to hold office until the next annual meeting of shareholders or until such director resigns or a successor is elected or appointed. Votes at the Meeting were as follows:

Director	Votes For	% For	Votes Against	% Against
Frank Gleeson	9,473,905	99.94	5,348	0.06
Franklin M. Berger	9,478,576	99.99	677	0.01
Brian Bloom	9,476,755	99.97	2,498	0.03
Stephanie Brown	8,741,404	92.22	737,849	7.78
Selwyn Ho	9,473,538	99.94	5,715	0.06
Iris Loew-Friedrich	7,939,800	83.76	1,539,453	16.24
Geoff Mackay	9,449,959	99.69	29,294	0.31
Adam Mostafa	9,450,311	99.69	28,942	0.31
Mark Nawacki	9,477,041	99.98	2,212	0.02

2. By resolution passed by way of ballot, PricewaterhouseCoopers LLP was appointed as auditor of the Company to hold office until the next annual meeting or until its successor is appointed, and the directors were authorized to fix its remuneration. 98.69% of the votes represented in person or by proxy at the Meeting were in favour of the appointment and 1.31% were withheld from voting.

In total, approximately 55.33% of the issued and outstanding shares were represented in person or by proxy at the Meeting.

Yours very truly,

/s/ Liz Williams

Chief Financial Officer and Corporate Secretary

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 10.2 KB